Michele B. Kaufman, PharmD, CGP, RPh, is a freelance medical writer based in New York City and a pharmacist at New York Presbyterian—Lower Manhattan Hospital.
References
- Eli Lilly Clinical Pipeline. April 24, 2014. http://www.lilly.com/SiteCollectionDocuments/Pipeline/Clinical%20Development%20Pipeline/index.html. Accessed May 20, 2014.
- EULAR abstract OP0047: Baricitinib, an oral Janus kinase inhibitor, in the treatment of rheumatoid arthritis: Safety and efficacy in open-label, long-term extension study; Lilly and Incyte announce baricitinib efficacy and safety data from the open-label, long-term extension of the phase 2b JADA study in patients with rheumatoid arthritis—Results from 52-week study presented at EULAR 2013. June 13, 2013. http://lilly.mediaroom.com/index.php?s=9042&item=137205. Accessed May 20, 2014.
- Johnsen M. Pfizer launches ‘Purple Pill’ Nexium 24HR onto OTC shelves. May 27, 2014. http://www.drugstorenews.com/article/pfizer-launches-purple-pill-nexium-24hr-otc-shelves. Accessed June 25, 2014.
- Brunner HI, Ruperto N, Zuber Z, et al. Efficacy and safety of tocilizumab in patients with polyarticular-course juvenile idiopathic arthritis: Results from a phase 3, randomised, double-blind withdrawal trial. Ann Rheum Dis. 2014; May 16. DOI: 10.1136/annrheumdis-2014-205351.
- Roche receives EU approval for new subcutaneous formulation of RoACTEMRA providing more treatment flexibility for patients with moderate to severe rheumatoid arthritis. April 28, 2014. http://www.firstwordpharma.com/node/1205989#axzz32xnF7G00. Accessed May 27, 2014.
- FDA. April 2014. http://www.fda.gov/Safety/MedWatch/SafetyInformation/ucm299628.htm. Accessed May 26, 2014.
- FDA warns of next-day impairment with sleep aid Lunesta (eszopiclone) and lowers recommended dose. May 15, 2014. http://www.fda.gov/downloads/Drugs/DrugSafety/UCM397277.pdf. Accessed May 27, 2014.
